Opaganib is under clinical development by RedHill Biopharma and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Opaganib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Opaganib overview
Opaganib (ABC-294640) is under development for the treatment of renal interstitial fibrosis, advanced, unresectable intra-hepatic, gastrointestinal acute radiation syndrome (GI-ARS), perihilar and extra-hepatic cholangiocarcinoma, non-small cell lung cancer, advanced solid tumors, pancreatic cancer, bile duct cancer (cholangiocarcinoma), colorectal cancer, metastatic castration resistant prostate cancer, Pseudomonas aeruginosa-induced lung injury, radiation-induced lung inflammation and fibrosis, acute kidney injury, pneumonia, coronavirus disease (COVID-19) and Ebola virus infection, chikungunya virus and respiratory syncytial virus (RSV) infection. It is under development for inflammatory bowel disease (IBD) including ulcerative colitis and Crohn's disease. It is administered orally as a capsule. It is an aryladamantane derivative. The drug candidate acts by targeting sphingosine kinase-2 (SK2), dihydroceramide desaturase and glucosylceramide synthase. The drug candidate is a new chemical entity. It was also under development for multiple myeloma, hepatocellular carcinoma, diffuse large B-cell lymphoma, kaposi sarcoma and retinopathy, primary effusion lymphoma, liver transplantation, ulcerative colitis and rheumatoid arthritis. It was also under development as a radioprotectant for the prevention of mucositis and head and neck cancer.
RedHill Biopharma overview
RedHill Biopharma (RedHill) is a specialty biopharmaceutical company that develops and commercializes therapeutics for gastrointestinal (GI) diseases and cancer. The company’s commercial product portfolio consists of branded prescription drugs including a combination of omeprazole, amoxicillin and rifabutin omeprazole; naloxegol; and rifamycin. RedHill is investigating its pipeline candidates for the treatment of Crohn’s disease, non-tuberculous mycobacterial infection (NTM) infections, gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), bowel cleanser, cancer and novel coronavirus disease (COVID-19). The company has a subsidiary in the US. RedHill is headquartered in Tel Aviv, Israel.
For a complete picture of Opaganib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
